340B Report reviewed a letter Novartis sent to an STD covered entity outlining its plans to end 340B pricing for STD clinics.

Novartis is Second Drugmaker to End 340B Pricing for STD Clinics

October 28, 2025 William Newton, Associate Editor/Senior Writer 340B Report Views

Novartis has begun informing STD clinics that they will lose access to 340B pricing for all of the company’s products [...]

Please Login or Become a Paid Subscriber to View this Content

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!